# Hongchen Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hongchen-biology

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.whhcbiology.com
- Latest round: Angel (Oct 18, 2024)
- Investors on record: 2

## About

Established in 2023 and based in Wuhan, China, Hongchen Biology operates as a biotech company that mainly provides innovative stem cell medicine. The co-founder and chairman of the company, Jun Tong graduated from Huazhong University of Science and Technology. In October 2024, it closed angel funding co-led by new investors Jiadaogu Capital and Rivercity Investment.

The company mainly provides innovative stem cell medicine. Products include autologous stem cell storage, IPSC-differentiated (Induced Pluripotent Stem Cell) mesenchymal stem cells, and MSC-derived (Mesenchymal Stem Cells) exosomes. The products are mainly used to treat spinal cord injuries.

The company generates revenue by providing innovative stem cell medicine for the treatment of spinal cord injuries.

The company will submit an IND application for a new drug for the treatment of spinal cord injury in H2 2025 and conduct a Phase I clinical trial in H1 2026. It will use the angel funding for the clinical application of cell therapy technology and to accelerate the marketization of the product.

## Funding rounds

- Angel, Oct 18, 2024 — Rivercity Investment, Jiadaogu Capital

## Investors

- Rivercity Investment (https://capitalatlas.ai/funds/rivercity-investment) — Angel
- Jiadaogu Capital (https://capitalatlas.ai/funds/jiadaogu-capital) — Angel